DBVT vs. BLUE, SGMO, BCAB, LIFE, OTLK, MOLN, OMGA, SCLX, CRIS, and PASG
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include bluebird bio (BLUE), Sangamo Therapeutics (SGMO), BioAtla (BCAB), aTyr Pharma (LIFE), Outlook Therapeutics (OTLK), Molecular Partners (MOLN), Omega Therapeutics (OMGA), Scilex (SCLX), Curis (CRIS), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
bluebird bio (NASDAQ:BLUE) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
bluebird bio has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
bluebird bio has a net margin of -419.64% compared to bluebird bio's net margin of -530.89%. DBV Technologies' return on equity of -34.32% beat bluebird bio's return on equity.
87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 2.1% of bluebird bio shares are owned by company insiders. Comparatively, 0.7% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
bluebird bio received 636 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 57.16% of users gave DBV Technologies an outperform vote.
DBV Technologies has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, bluebird bio and bluebird bio both had 10 articles in the media. bluebird bio's average media sentiment score of 0.53 beat DBV Technologies' score of 0.02 indicating that DBV Technologies is being referred to more favorably in the news media.
bluebird bio currently has a consensus target price of $5.74, indicating a potential upside of 457.71%. DBV Technologies has a consensus target price of $3.33, indicating a potential upside of 471.27%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than bluebird bio.
Summary
bluebird bio beats DBV Technologies on 10 of the 17 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
